Some side effects of simvastatin may occur that usually do not need medical attention.



Both statins are well tolerated with safety profiles similar to other members of the statin class. This site needs JavaScript to work properly. Reductions in plasma total and LDL cholesterol were significantly greater with 5 mg simvastatin (16 and 23%) compared to 10 mg pravastatin (12 and 18%; p < or = 0.01). These side effects may go away during treatment as your body adjusts to the medicine.

Efficacy was determined by measuring changes from baseline in lipid parameters including low-density lipoprotein (LDL) cholesterol, total cholesterol, triglycerides, and apolipoprotein B. Unable to load your delegates due to an error When administered at lower or equivalent daily doses, simvastatin was significantly more effective than pravastatin in … COVID-19 is an emerging, rapidly evolving situation. 2000 Jun;22(6):441-57. doi: 10.2165/00002018-200022060-00003.Drugs.

Unable to load your delegates due to an error At 6 and 12 weeks, a significantly higher percentage of simvastatin patients (45 and 59%, respectively) achieved a desirable LDL cholesterol level of < 130 mg/dl (< 3.4 mmol/l) compared to pravastatin patients (32-33%; p < or = 0.05). Epub 2008 Jun 14. dose of 10 mg/day, is more effective than simvastatin 10 mg/day at lowering lipids and reaching LDL cholesterol goals in patients with mixed dyslipidemia.

doi: 10.1016/s0002-9149(00)01430-2. Elsevier Science

doi: 10.1002/14651858.CD008226.pub3.Son JW, Kim DJ, Lee CB, Oh S, Song KH, Jung CH, Mok JO, Kim JH, Moon MK, Choi KM, Cho JH, Choi SH, Kim SK, Park KS, Kim HS, Kim IJ, Kim YI, Kim HJ, Kim SY, Kim S.J Diabetes Investig. S. Karger AG, Basel, Switzerland

Simvastatin belongs to a group of medicines called statins.. Both drugs were well tolerated and had comparable safety profiles. Unable to load your collection due to an error 2016;2016:2601740. doi: 10.1155/2016/2601740. Olsson AG, Eriksson M, Johnson O, Kjellström T, Lanke J, Larsen ML, Pedersen T, Tikkanen MJ, Wiklund O; 3T Study Investigators.Clin Ther. The 6-week efficacy and safety of atorvastatin versus simvastatin was determined during a 54-week, open-label, multicenter, parallel-arm, treat-to-target study. 2013 Sep 13;4(5):466-74. doi: 10.1111/jdi.12074.



Both statins are well tolerated with safety profiles similar to other members of

Atorvastatin: 10 mg, 20 mg, 40 mg, and 80 mg The costs of generic simvastatin and atorvastatin are both fairly low, with generic simvastatin being slightly less expensive. After 24 weeks of simvastatin treatment (with dosages increasing from 10, 20 and up to 40 mg daily at 8- week intervals),simvastatin decreased the mean LDL-C by 36.8 % (placebo: 1.1 % increase from baseline), Apo B by 32.4 % (placebo: 0.5 %), and median TG levels by 7.9 % (placebo: 3.2 %) and increased mean HDL-C levels by 8.3 % (placebo: 3.6 %). 1993 Jul;234(1):77-82. doi: 10.1111/j.1365-2796.1993.tb00708.x.Ann Pharmacother.

Clipboard, Search History, and several other advanced features are temporarily unavailable. 2003 Jan;25(1):119-38. doi: 10.1016/s0149-2918(03)90015-4.Clin Cardiol. 1996 Jan;14(1):11-24. doi: 10.2165/00002018-199614010-00003.Am J Cardiol. Elsevier Science Clipboard, Search History, and several other advanced features are temporarily unavailable. 2011 Nov;12(3):277-84. doi: 10.1016/S1567-5688(11)70887-X.Jung WS, Kwon S, Cho SY, Park SU, Moon SK, Park JM, Ko CN, Cho KH.Evid Based Complement Alternat Med. Simvastatin and pravastatin, two 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, were compared in a multinational, randomized, double-blind trial. Name must be less than 100 characters 143) or 10 mg/day pravastatin (n = 138); the simvastatin dose was increased to 10 mg for an additional 6 weeks while the pravastatin dose remained at 10 mg. Epub 2013 Mar 26.Cardiovasc Drugs Ther. 2008 Aug;22(4):321-38. doi: 10.1007/s10557-008-6113-z. Diabetic patients treated with either statin had safety characteristics similar to nondiabetics, with atorvastatin exhibiting superior efficacy to simvastatin. Compared with simvastatin, atorvastatin produced significantly greater (p < 0.0001) reductions from baseline in LDL cholesterol (37.2% vs 29.6%), total cholesterol (27.6% vs 21.5%), triglycerides (22.1% vs 16.0%), the ratio of LDL cholesterol to high-density lipoprotein (HDL) cholesterol (41.1% vs 33.7%), and apolipoprotein B (28.3% vs 21.2%), and a comparable increase from baseline in HDL cholesterol (7.4% vs 6.9%).

Atorvastatin was also significantly (p < 0.0001) more effective than simvastatin at treating the overall patient population to LDL cholesterol goals (55.6% vs 38.4%). The efficacy of 10 mg simvastatin in lowering these lipid parameters was also superior (19 vs. 11% and 27 vs. 17%, respectively; p < or = 0.01). In primary hypercholesterolemia, atorvastatin 10 mg was more effective and nonequivalent to simvastatin 20 mg and significantly more effective than simvastatin 10 mg … 1995 Jul-Aug;29(7-8):743-59. doi: 10.1177/106002809502907-818.Cardiovasc Drugs Ther.